Tag: US
Revenues of Indian pharma companies likely to expand by 9-11% in...
Revenues estimated to increase by 9-11% from the US market, and 7-9% each from the European and the domestic markets in FY2025
Lupin completes Phase 3 trials for Lucentis Biosimilar
The successful completion of the global Phase 3 trials paves the way to obtain marketing approval in the U.S. and EU
Enzene launches discovery services division at BIO 2024
CDMO provides end-to-end drug discovery, development and commercialization services with sites in both the USA and Asia
India Unlimited: ICPA event in San Diego on 2nd June to...
Happening on the sidelines of US BIO 2024, the event will see top experts sharing their perspective on how international stakeholders can benefit from outsourcing their requirements to India
Biocon Biologics obtains US-FDA approval for biosimilar Aflibercept for Yesafili
A significant milestone for the company marking its entry into ophthalmology, a new therapeutic area in the United States
Sentynl Therapeutics, a Zydus Group company announces global acquisition of Zokinvy
Zokinvy is approved in the US, European Union and Great Britain, and Japan for the treatment of Progeria, a collection of ultra-rare, fatal, genetic premature aging diseases that accelerate mortality in young patients
Concept Medical enrolls first patient in ‘Magical-ISR’ IDE study in US
The MAGICAL-ISR IDE study aims to assess the safety & efficacy of this Sirolimus DCB in treating ISR, focusing on the proportion of patients avoiding TLF within 1 year post-procedure
Veeda Clinical Research acquires European CRO ‘Heads’
With this acquisition, Veeda’s global pharmaceutical and biotech clients can now leverage the unique and unparalleled suite of early to late-phase CRO services across Europe, US, and Asia Pacific
SynaptixBio awarded second FDA Orphan Drug Designation to boost search for...
The leading biotech company is now aiming to develop treatment for second variant of TUBB4A leukodystrophy
“There are inconstancies across biosimilar classes right now”
Thomas Newcomer, VP, Head of US Market Access, Samsung Bioepis shares insightful perspectives on the US and Indian biosimilar markets